Research And Markets Research And Markets
0 CHECKOUT

Lymphoma Drugs Market Research Reports

Lymphoma encompasses a variety of blood cancers of the lymphatic system. Non-Hodgkin’s Lymphoma (NHL) for example, is diagnosed in over 100,000 every year in the US and EU combined. An array of expert reports in our Lymphoma Section enable you to investigate drug development strategies and market trends for NHL, Hodgkin’s Lymphoma, Skin Lymphoma, T-Cell Lymphoma, Indolent Lymphoma and other variants. Investigate key issues such as licensing, R&D, industry alliances, generic drugs (rituximab, bortezomib, doxorubicin, bleomycin, vinblastine, etc.) and the activities of major pharmaceutical players such as Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, and Sanofi-Aventis. Show Less Read more

NHL: Diffuse Large Bcell Lymphoma: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis

An increase in disease prevalence and the launch of new targeted therapies across a range of treatment settings will drive the growth of the diffuse large B-cell lymphoma (DLBCL) market during 2016-25...

Published:  May 2016
Price:  From EURUSDGBP

Nhl: Mantle Cell Lymphoma: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis

An increase in incident cases, combined with the expanded use of costly treatments such as Imbruvica and Revlimid, will drive the growth of the mantle cell lymphoma (MCL) market during 2016-25. This...

Published:  April 2016
Price:  From EURUSDGBP

Nhl: Follicular Lymphoma: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis

The follicular lymphoma (FL) market will continue to grow during 2016-25, despite the entry of biosimilars and generics, due to an increase in disease incidence and the launch of new pipeline therapies. This...

Published:  April 2016
Price:  From EURUSDGBP

Global T-Cell Lymphoma Market & Clinical Pipeline Insight

Immune system consists of various cells that impart resistance to body against foreign entities. They also prevent the development of aberrant cells in the body to maintain its normal functioning. However,...

Published:  March 2016
Price:  From EURUSDGBP

Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight

The market for Non Hodgkin Lymphoma has significant unmet medical necessities in terms of demand for innovative drugs and novel technologies. This is one of the major factors behind the market witnessing...

Published:  November 2014
Price:  From EURUSDGBP

Target Atlas in Lymphoma: A Competitive Outlook

Extra value: One year of free online updates included with this product "Target Atlas in Lymphoma: A Competitive Outlook" helps you to understand the complex world of commercial development in lymphoma...

Published:  August 2016
Price:  From EURUSDGBP

Cutaneous T-Cell Lymphoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

Our Report, “Cutaneous T-Cell Lymphoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline...

Published:  September 2016
Price:  From EURUSDGBP

Peripheral T-Cell Lymphomas (PTCL)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

Our Report, “Peripheral T-Cell Lymphomas (PTCL)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III...

Published:  September 2016
Price:  From EURUSDGBP

T-Cell Lymphomas-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

Our Report, “T-Cell Lymphomas-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs...

Published:  September 2016
Price:  From EURUSDGBP

Follicular Lymphoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

Our Report, “Follicular Lymphoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs...

Published:  September 2016
Price:  From EURUSDGBP

Mycosis Fungoides-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

Our Report, “Mycosis Fungoides-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs...

Published:  September 2016
Price:  From EURUSDGBP

Hodgkin Lymphoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

Our Report, “Hodgkin Lymphoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs...

Published:  September 2016
Price:  From EURUSDGBP

Mantle Cell Lymphoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

Our Report, “Mantle Cell Lymphoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs...

Published:  September 2016
Price:  From EURUSDGBP

Acute Lymphoblastic Lymphoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

Our Report, “Acute Lymphoblastic Lymphoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline...

Published:  September 2016
Price:  From EURUSDGBP

Lymphoblastic Lymphoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

Our Report, “Lymphoblastic Lymphoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline...

Published:  September 2016
Price:  From EURUSDGBP

Burkitt Lymphoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

Our Report, “Burkitt Lymphoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs...

Published:  September 2016
Price:  From EURUSDGBP

Non-Hodgkin Lymphoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

Our Report, “Non-Hodgkin Lymphoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs...

Published:  September 2016
Price:  From EURUSDGBP

Lymphoma Drug Pipeline Update

Lymphoma is a broad term encompassing a variety of cancers of the lymphatic system. There are today 383 companies plus partners developing 568 lymphoma drugs in 1073 developmental projects in cancer....

Published:  August 2016
Price:  From EURUSDGBP

Lymphoma Drug Pathway Analyzer

Extra value: One year of free online updates included with this product There are today at least 563 targeted molecular therapies known to affect more than 244 specific intracellular signaling pathways...

Published:  August 2016
Price:  From EURUSDGBP

Mantle Cell Lymphoma - Pipeline Review, H2 2016

Mantle Cell Lymphoma - Pipeline Review, H2 2016 Summary ‘Mantle Cell Lymphoma - Pipeline Review, H2 2016’, provides an overview of the Mantle Cell Lymphoma pipeline landscape. The report provides...

Published:  August 2016
Price:  From EURUSDGBP
Loading Indicator